Recombinant Rat Fas protein (mFc Tag)
种属
Rat
纯度
>90 %, SDS-PAGE
标签
C-mFc
生物活性
未测试
验证数据展示
产品信息
| 纯度 | >90 %, SDS-PAGE |
| 内毒素 | <0.1 EU/μg protein, LAL method |
| 生物活性 |
Not tested |
| 来源 | HEK293-derived Rat Fas protein Gln22-Lys170 (Accession# Q63199) with a mouse IgG Fc tag at the C-terminus. |
| 基因ID | 246097 |
| 蛋白编号 | Q63199 |
| 预测分子量 | 43.4 kDa |
| SDS-PAGE | 46-60 kDa, reducing (R) condition |
| 组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| 复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| 储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
FASN (fatty acid synthase, also named Fas) is a multi-enzyme protein that serves as the key regulator in lipid metabolism, especially fatty acid synthesis. Upregulated FASN expression has been reported to be associated with cancer progression in multiple cancer types, such as prostate cancer, ovarian cancer, breast cancer, and liver cancer. FASN may serve as an oncogenic factor due to its role in regulating cancer cell fatty acid synthesis or driving aberrant lipogenesis in cancer cells. In cervical cancer, studies have utilized gene expression analysis to identify FASN as a potential prognostic or therapeutic target.
参考文献:
1. Flavin R, et al. (2010). Future Oncol. 6:551–562. 2. Che L, et al.(2020). Gut. 69:177–186. 3. Roszik J, et al. (2018). Front Immunol. 9:2102. 4. Xia L, et al. (2018). Front Oncol. 8:368.
